US05280R1005 - ADR
AUTOLUS THERAPEUTICS PLC
NASDAQ:AUTL (4/19/2024, 9:14:00 AM)
4.745
-0.05 (-1.15%)
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The company is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. The company has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
AUTOLUS THERAPEUTICS PLC
The Mediaworks, 191 Wood Lane
London W12 7RZ
P: 442038296230
CEO: Christian Itin
Employees: 399
Website: https://www.autolus.com/
Autolus Therapeutics Announces Changes to its Board of Directors...
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates...
Here you can normally see the latest stock twits on AUTL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: